Linkedbio is the newly launched services provided by Lingmed.
We help companies to understand and monitor China market opportunities, define the right strategies
and work with the right partners
-
Linkedbio Partnering:
Lingmed analyst team evaluates the innovative biotech products, technologies and medical devices to estimate the market size, risk & opportunities, to identify the right partner for the asset. Lingmed team will arrange partnering meetings to facilitate the direct dialogues, suggest deal structure to support deal closing
-
Linkedbio Analysis:
Lingmed analyst team conducts desk researches and interviews to get insights on China market, we provide tailored product China market sizing analysis, deal valuation and competitive landscape reports to our clients
Latest Lingmed asset recommendation
Lingmed asset recommendation
Seeking Global Collaboration for a Novel Androgenetic Alopecia Project (Monday, 23 Dec 2024)
- Epidemiology of Androgenetic Alopecia
- Treatment of Androgenetic Alopecia in China
- Lingmed Project Recommendation: Androgenetic Alopecia Project (Project Description, Project Phase, Indication, Project Needs, Project Highlights, Company Profile)
Related asset recommendations
Best-in-Class Intestinal Inflammation Project Seeking Global Collaboration
European Innovation: High-Potential Anti-Inflammatory and Anti-Fibrotic Project Seeking Global Collaboration – LMP2706
Latest Lingmed monthly webinar
Analysis of drug targets and key pharmaceutical companies in pain therapeutic area, are you ready? (Thursday, 14 Nov 2024)
Event details
- Potential innovative targets for new pain drugs
- Breakthroughs and innovations of non-addictive pain drugs
- Competition landscape of the top 10 domestic companies in pain therapeutic area
- An innovative biotech roadshow
Related monthly webinars
Application of nano-antibodies in autoimmune diseases, are you ready?
Breakthroughs & progress of antiepileptic drugs, are you ready?
General information
| Product |
> |
440 |
| Company |
> |
819 |
| Deals |
> |
206 |
| Reports |
> |
161 |
| Non-confi PDF |
> |
174 |